DOI: 10.1182/blood-2022-169777
Paper Summary:
Title: Low Dose Dasatinib Is Not As Active in a CML CP Cohort Enriched with Intermediate/High-Risk CML Chronic Phase: A Phase IIb Multi-Center Trial
Author(s): Abraham, Aby (author);Jain, Hasmukh (author);Bhattacharyya, Jina (author);Biswajit, Dubashi (author);PK, Jayachandran (author);Bhurani, Dinesh (author);Bala, Stalin Chowdary (author);Pramanik, Suman (author);Devadas, Santhosh (author);Kulkarni, Uday Prakash (author);Sengar, Manju (author);Ahmed, Rayaz (author);Mani, Thenmozhi (author);Das, Damodar (author);Karunakaran, Parathan (author);Gundeti, Sadashivudu (author);Pallasseri, Rasmi (author);Patkar, Nikhil (author);Nookala, Manjunath (author);Kayal, Smita (author);Balasubramanian, Poonkuzhali (author)
Year: 2022
DOI: 10.1182/blood-2022-169777
URL: https://doi.org/10.1182/blood-2022-169777
Download Paper from Sci-Hub:
✍: FYIcenter.com
2024-10-25, ∼544👍, 0💬
Related Topics: